Stony Brook Receives $3.5 Million to Establish ‘Bahl Molecular Imaging Laboratory’
The high-tech lab will feature a cyclotron to enhance diagnostic capabilities
STONY BROOK, NY, May 16, 2014 - Kavita and Lalit Bahl of Stony Brook have pledged $3.5 million to establish the Kavita and Lalit Bahl Molecular Imaging Laboratory at Stony Brook Medicine. The high-tech laboratory will enable Stony Brook physicians and researchers to diagnose and monitor disease at the molecular level, as well develop new targeted treatments for cancer, neurological disorders, and other diseases. Plans for the laboratory include a cyclotron, a particle accelerator that is used in medicine to create radioactive tracer molecules to enhance diagnostic capabilities or treat specific diseases, particularly cancer.
The Bahl Molecular Imaging Laboratory will be located in Stony Brook’s Medical and Research Translation (MART) building. Part of Stony Brook Medicine’s $423 million expansion project, the 245,000 square-foot, eight-story MART will foster research to help better understand the basis for human disease and where scientific discovery will be translated into clinical research. As part of its core mission, the MART will be devoted to cancer research and care, and ultimately where promising patient results can be turned into FDA-approved healthcare diagnostic and treatment options. The MART will also house Stony Brook Medicine’s Cancer Center and advanced biomedical imaging and biomedical informatics programs.
“We are extremely grateful for the generosity of Kavita and Lalit Bahl, and their visionary contribution to Stony Brook’s medical imaging program,” said President Samuel L. Stanley Jr. MD. “The Bahl Molecular Imaging Laboratory and the new Cyclotron will enhance real time diagnostic capabilities and at the same time will provide the resources our faculty and students need to advance cancer research and treatment to a higher level.”
Lalit Bahl, an employee of Renaissance Technologies, and his wife, Kavita, were inspired to give to Stony Brook in light of Renaissance founder Jim Simons’ matching gift program to the University. Upon learning about Stony Brook’s history in medical imaging discoveries – starting in the 1970s when a Stony Brook Chemistry professor, Paul Lauterbur, developed magnetic resonance imaging (MRI) technology and subsequently received a Nobel Prize – the Bahls decided to help Stony Brook establish a molecular imaging laboratory.
“Stony Brook has been a notable leader in both discovering and using breakthrough imaging technology for research and clinical purposes,” said Lalit Bahl. “Kavita and I are certain that the cyclotron and molecular imaging offer the promise of important discoveries related to cancer and other diseases.”
The cyclotron will complement and further enhance Stony Brook’s Positron Emission Tomography (PET)/MRI technology, which provides imaging results with a more precise and accurate assessment of disease. In 2013, Stony Brook became the first institution on Long Island to acquire a PET/MRI scanner.
“This gift will make a huge impact on our medical imaging program, clinical capabilities and new Department of Biomedical Informatics,” said Kenneth Kaushansky, MD, Senior Vice President of the Health Sciences and Dean of the School of Medicine. “Our use of cutting-edge molecular imaging in conjunction with computer technology to analyze biological data will be a catalyst toward increasing our abilities to understand disease processes, make earlier diagnoses, and better treat patients.”
Dexter Bailey, Executive Director of the Stony Brook Foundation, added, “Philanthropists invest in success. The Bahl Laboratory supports the kind of translational and clinical research that will lead to discoveries that change lives.”
Lalit and Kavita Bahl